Double-digit growth for AZ

Friday 30 July 2021

United Kingdom

AstraZeneca Plc reported double-digit revenue growth for the second quarter and first half year driven by several oncology medicines and by Farxiga, a diabetes drug recently approved in the US for chronic kidney disease.

Read in full with a subscription

Learn more about subscribing to MedNous.